title: A phase II study of etoposide, cisplatin plus methotrexate in patients with advanced refractory breast cancer.
authors.forename: M
authors.initials: M
authors.lastname: Jouve
authors.forename: T
authors.initials: T
authors.lastname: Dorval
authors.forename: V
authors.initials: V
authors.lastname: Mosseri
authors.forename: T
authors.initials: T
authors.lastname: Palangie
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
authors.forename: E
authors.initials: E
authors.lastname: Garcia-Giralt
authors.forename: A
authors.initials: A
authors.lastname: Livartowski
authors.forename: S
authors.initials: S
authors.lastname: Scholl
authors.forename: P
authors.initials: P
authors.lastname: Pouillart
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D016879:Salvage Therapy
chemical_list: D005047:Etoposide; D002945:Cisplatin; D008727:Methotrexate